Abstract Details

Title Message Framing to Determine Best Methods for Discussing Migraine Behavioral Treatments with Persons with Migraine.

Topic Headache

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-010

Objective To assess for associations between message framing and migraine patients’ willingness to seek behavioral treatment.

Background Behavioral treatments for migraine prevention are safe and effective but under-utilized in migraine management. Health message framing might be helpful in guiding patients with treatment decisions.

Design/Methods We developed four message frames for Turk Prime participants who screened positive for migraine using the American Migraine Prevalence and Prevention (AMPP) screen: Specific Loss Framing (SLF), Specific Gain Framing (SGF), Nonspecific Loss Framing (NSLF), Nonspecific Gain Framing (NSGF). The message frames were randomly distributed.

Results

There are 401 participants. Mean age was 35.80+10.12[19-68] years. More than two third of participants (70.3%) were women. Mean number of headache days/ month is 6.5. Some (14.7%) used evidence-based behavioral therapy for migraine. Out of the 401 participants, broken down as 101 SLF, 98 SGF, 100 NSLF and 102 NSGF, there are no significant differences in willingness to pursue behavioral treatment for migraine between the message framing groups (respective Likert scale means for willingness to pursue in-person behavioral treatment are: 3.6, 3.7, 3.6, and 3.5 ANOVA p-value 0.99, and for willingness to pursue smart-phone based are: 3.6, 3.7, 3.7, and 3.7 ANOVA p-value 0.14). Across all message frame groups, the majority of participants felt somewhat likely to try in-person (64.8%) or smart phone-based (63.1%) behavioral therapy for migraine, and 56.4% are not willing to try behavioral therapy for migraine if they had to pay out of pocket.

Conclusions Message framing is not associated with willingness to seek behavioral therapy for migraine. However, when provided with the descriptions of behavioral therapy in general, most participants indicate that they would be somewhat likely to try behavioral therapy for migraine provided they do not have to pay for it out of pocket.

Authors/Disclosures
Adama Jalloh PRESENTER	No disclosure on file
Olivia Begasse De Dhaem, MD (Institute for Headache and Brain Health)	Dr. Begasse De Dhaem has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Begasse De Dhaem has received personal compensation in the range of $500-$4,999 for serving as a Consultant for JOGO. Dr. Begasse De Dhaem has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Begasse De Dhaem has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pain Medicine Journal. Dr. Begasse De Dhaem has received publishing royalties from a publication relating to health care.
Mia T. Minen, MD, FAAN (NYULMC Neurology)	The institution of Dr. Minen has received research support from NIH. Dr. Minen has received intellectual property interests from a discovery or technology relating to health care. Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a First Contact-Primary Care Advisory Board Member with American Headache Society . Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PCORI grant on migraine evidence based map for stakeholders with ECRI .

��ɫ��

��ɫ��